WASHINGTON, D.C. — January 14, 2015 — India was certified polio-free in 2014. Today, the country has its sights set on another public health victory: the elimination of lymphatic filariasis, a neglected tropical disease (NTD) that threatens nearly half of its population. To meet this ambitious goal, the Indian Ministry of Health & Family Welfare (MOHFW) has launched one of the largest public health campaigns in India’s history to provide more than 400 million people with free medication that could protect them from lymphatic filariasis.
WASHINGTON, D.C. — December 16, 2014 — The Sabin Vaccine Institute, through the Coalition against Typhoid (CaT) Secretariat, announced today that it has received an award of approximately US$ 5 million from the Bill & Melinda Gates Foundation to support the establishment of an Asia regional enteric fever surveillance network. The network will enable the systematic collection of data in order to fill knowledge gaps on the impact of severe typhoid and paratyphoid — diseases collectively referred to as enteric fever.
WASHINGTON, D.C. — December 10, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its Board of Trustees unanimously appointed Axel Hoos, MD, PhD, to serve as the interim Chairman of the Board. Building upon the past successes of late Chairman Morton P. Hyman, Dr. Hoos will be instrumental to providing continuity to the institute and to Sabin’s efforts in launching new programs, clinical trials and advocacy campaigns around the world.
Washington, DC - December 4, 2014 Four eminent scientists have agreed to serve as U.S. Science Envoys beginning in January, 2015: Dr. Peter Hotez, Dr. Jane Lubchenco, Dr. Arun Majumdar, and Dr. Geri Richmond. Announced by President Obama in Cairo in June 2009, the U.S. Science Envoy program demonstrates the United States’ commitment to science, technology, and innovation as tools of diplomacy and economic growth.
Morton P. Hyman, a renowned philanthropic and public health leader and Chariman of the Sabin Vaccine Institute Board of Trustees, passed away peacefully yesterday surrounded by his family and loved ones. The following is a statement from Sabin’s CEO, Ambassador Michael W. Marine, reflecting on the profound difference that Mort made during his lifetime.
WASHINGTON, D.C. — September 25, 2014 — The Sabin Vaccine Institute (Sabin) today announced that effective October 17, 2014, Dr. Jon Andrus will join Sabin as Executive Vice President and Director of Vaccine Advocacy and Education. In this role, he will leverage more than three decades of experience as a global health leader with a well-documented record for fostering collaboration among national governments and partners to expand access to vaccines for the world’s poorest people.
Durban, South Africa — 22 September 2014 — The International Association of Immunization Managers (IAIM) Secretariat, based at the Sabin Vaccine Institute (Sabin), today announced it will hold its first-ever regional meeting for members from the Middle East and Africa on 25-26 September 2014 in Durban, South Africa.
WASHINGTON, D.C. — September 16, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) received $2 million from the Global Health Innovative Technology Fund (GHIT Fund) to develop a new therapeutic vaccine formulation for Chagas disease. Baylor College of Medicine, Eisai Co., Ltd. (Eisai) and Aeras are partnering on this project with the Sabin PDP, based at the Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development in Houston, Texas.
03 SEPTEMBER 2014– Sanofi Pasteur, the vaccines division of the French pharmaceutical company Sanofi, announced in a press release the preliminary results of a Phase 3 trial of its candidate dengue vaccine conducted in five countries in Latin America.
WASHINGTON, D.C. — September 3, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas.